Sun Pharma ends attempt to gain full control of Taro

INICIO/Noticias Farmacéuticas | Posted 22/02/2013 post-comment0 Post your comment

Sun Pharmaceutical Industries (Sun Pharma) announced on 8 February 2013 that it had given up on its effort to buy the remaining stock of Taro Pharmaceutical Industries (Taro) for about US$685 million after Taro shareholders held out for a higher price.

Generic V13C05

India-based generics manufacturer Sun Pharma only managed to gain a controlling stake in Israel’s Taro in September 2010 after a prolonged legal battle [1], and currently holds 66% of Taro’s shares [2].

Sun Pharma offered in October 2011 to buy all outstanding shares of Taro, not currently held by Sun Pharma, at a price of US$24.50 per share [2]. However, despite this offer being increased by almost 60% to US$39.50 per share in August 2012 [3], Taro shareholders still rejected the deal. The shareholders already believed in October 2011 that a fair value for Taro would have been at least US$48.50 per share [2], which Sun Pharma was not willing to offer.

Sun Pharma has been battling to take over Taro since May 2007, when Taro was a struggling company and Sun Pharma first bought shares in Taro [1]. Since that time, however, Taro has become profitable, with its share price quickly surpassed the offer from Sun Pharma. Taro’s closing share price on the New York Stock Exchange on 7 February 2013 was US$50.55.

‘As earnings keep coming in stronger and stronger for Taro, there was obviously a lot of disconnect with the price Sun [Pharma] was willing to offer,’ IDFC Securities analyst Nitin Agarwal told Bloomberg. He added that it was ‘fairly unlikely that the deal would have gone through’.

The two companies stated that the termination of the merger agreement ‘was in the best interest of the respective companies and shareholders’.

Reference

1.  GaBI Online - Generics and Biosimilars Initiative. Sun Pharma finally wins battle for Taro [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Feb 22]. Available from: www.gabionline.net/Pharma-News/Sun-Pharma-finally-wins-battle-for-Taro

2.  GaBI Online - Generics and Biosimilars Initiative. Sun Pharma offers to buy remaining Taro shares [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Feb 22]. Available from: www.gabionline.net/Pharma-News/Sun-Pharma-offers-to-buy-remaining-Taro-shares

3.  GaBI Online - Generics and Biosimilars Initiative. Sun Pharma finally gains full control of Taro [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Feb 22]. Available from: www.gabionline.net/Pharma-News/Sun-Pharma-finally-gains-full-control-of-Taro

Permission granted to reproduce for personal and educational use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Sun Pharma, Taro

comment icon Comments (0)
Post your comment
Related content
Genfar: La nueva marca de genéricos de Eurofarma en América Latina
10 AA008993
INICIO/Noticias Farmacéuticas Posted 12/12/2023
Cuba y China estrechan lazos en biotecnología
134 AA010709
INICIO/Noticias Farmacéuticas Posted 01/09/2023
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010